Genentech, part of the Roche Group, has presented compelling results from the Phase III INAVO120 study, evaluating the effectiveness of inavolisib in combination with palbociclib (Ibrance) and fulvestrant for treating a specific group of breast cancer patients. The study focuses on individuals with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. […]
Roche, a global leader in pharmaceuticals, announced positive results from its Phase III INAVO120 study, testing the investigational therapy inavolisib in combination with palbociclib (Ibrance) and fulvestrant. This study targeted patients with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The trial met its primary endpoint, showing a significant improvement in […]
